CSL
Phone: 61 3 9389 1911
Fax: 61 3 9389 1434
Web: https://www.csl.com
Type | Public |
---|---|
Traded as |
|
Industry | Biotechnology |
Founded | 1916 (Federal government department), 1994 (privatised) |
Headquarters | Parkville, Melbourne, Victoria, Australia (Global), |
Key people | Paul Perreault (CEO) |
Products | blood plasma, vaccines, antivenom, other laboratory and medical products |
Revenue | AUD$10.61 billion (2021) |
Net income | USD$1.919 billion (2019) |
Number of employees | 30,000 person (2022) |
Divisions |
|
Website | www.csl.com |
Delivering on promises is what we do at CSL. Over a century ago in Melbourne, Victoria, Australia, we made a promise to save lives and protect the health of people who were stricken with a range of serious and chronic medical conditions. Today, as a leading global biotech company, that same promise has never been stronger. We develop and deliver innovative biotherapies and influenza vaccines that save lives, and help people with life-threatening medical conditions live full lives. We are driven by our deep passion to serve hundreds of thousands of patients and other stakeholders around the world.
For detailed contact information visit location pages below.
CSL's locations around the world
Oceania
Clinical Trials sponsored by CSL
-
CSL BehringNot yet recruiting
-
CSL BehringRecruiting
-
CSL BehringRecruiting
-
CSL BehringRecruitingTraumatic InjuryUnited States, United Kingdom, Australia
-
CSL BehringActive, not recruiting
-
CSL BehringActive, not recruitingHereditary AngioedemaAustralia, Canada, United States, New Zealand, Germany, Hong Kong, Netherlands, Taiwan, Czechia, Israel, Hungary, Japan, Russian Federation, Spain
-
CSL BehringCompletedIdiopathic Pulmonary FibrosisUnited States, Canada, United Kingdom, Australia, Germany, Poland, Belgium, Austria, Denmark, Italy, Spain
-
CSL BehringCompletedDiffuse Cutaneous Systemic SclerosisAustralia, Germany, Poland, Italy, United Kingdom